The Impact of Microsatellite Instability Status and Sidedness of the Primary Tumor on the Effect of Cetuximab-Containing Chemotherapy in Patients with Metastatic Colorectal Cancer.

about

The Impact of Microsatellite Instability Status and Sidedness of the Primary Tumor on the Effect of Cetuximab-Containing Chemotherapy in Patients with Metastatic Colorectal Cancer.

Item

http://www.wikidata.org/entity/Q41721762

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

The Impact of Microsatellite I ...... Metastatic Colorectal Cancer.

@en

type

Item

label

The Impact of Microsatellite I ...... Metastatic Colorectal Cancer.

@en

prefLabel

The Impact of Microsatellite I ...... Metastatic Colorectal Cancer.

@en

P1476

The Impact of Microsatellite I ...... Metastatic Colorectal Cancer.

@en

P2093

Ho Yeong Lim

http://www.w3.org/2001/XMLSchema#string

Jeeyun Lee

http://www.w3.org/2001/XMLSchema#string

Joon Oh Park

http://www.w3.org/2001/XMLSchema#string

Se Hoon Park

http://www.w3.org/2001/XMLSchema#string

Seung Tae Kim

http://www.w3.org/2001/XMLSchema#string

Su-Jin Lee

http://www.w3.org/2001/XMLSchema#string

Won Ki Kang

http://www.w3.org/2001/XMLSchema#string

Young Suk Park

http://www.w3.org/2001/XMLSchema#string

P2860

Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis

Global cancer statistics

PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer

Systematic review of microsatellite instability and colorectal cancer prognosis

Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma

P304

2809-2815

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.7150/JCA.18286

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-08-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28928870

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

cetuximab

P932

5604213

http://www.w3.org/2001/XMLSchema#string